UK Markets closed

Apontis Pharma AG (APPH.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
13.90-0.30 (-2.11%)
As of 09:32AM CEST. Market open.
Full screen
Loading interactive chart…
  • EQS Group

    APONTIS PHARMA holds Annual General Meeting 2022 - shareholders approve all agenda items with large majorities

    DGAP-News: APONTIS PHARMA AG / Key word(s): AGM/EGMAPONTIS PHARMA holds Annual General Meeting 2022 - shareholders approve all agenda items with large majorities 12.05.2022 / 15:00 The issuer is solely responsible for the content of this announcement.APONTIS PHARMA holds Annual General Meeting 2022 - shareholders approve all agenda items with large majoritiesMonheim am Rhein, 12 May 2022. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single

  • EQS Group

    APONTIS PHARMA continues strong profitable growth in Q1 2022

    DGAP-News: APONTIS PHARMA AG / Key word(s): Quarterly / Interim StatementAPONTIS PHARMA continues strong profitable growth in Q1 2022 10.05.2022 / 07:30 The issuer is solely responsible for the content of this announcement.APONTIS PHARMA continues strong profitable growth in Q1 2022 Single Pill revenues +40% to EUR 8.7 million remain main growth driver Single Pill revenue share increases to 61% (3M 2021: 57%) Total revenues grow faster than pharma sector by 31% to EUR 14.3 million EBITDA increas

  • EQS Group

    APONTIS PHARMA and Develco Pharma enter development partnership for launch of two Single Pills with pan-European intellectual property rights

    DGAP-News: APONTIS PHARMA AG / Key word(s): Product LaunchAPONTIS PHARMA and Develco Pharma enter development partnership for launch of two Single Pills with pan-European intellectual property rights 05.05.2022 / 07:30 The issuer is solely responsible for the content of this announcement.APONTIS PHARMA and Develco Pharma enter development partnership for launch of two Single Pills with pan-European intellectual property rights Further expansion of the mid-term Single Pill portfolio for the treat